• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1267158 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ }. n  P9 B+ j) P- @8 h1 e: uNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
* v# R8 d6 U, d8 S. {. g1 A' f( l# v+ Author Affiliations
1 t4 Q2 D# t) C( V# v( f% g1 M: T' l2 u% `3 U, |% f
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 5 N4 Z# e5 [+ L, g6 z) d6 I' T; v3 d
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 0 D0 N0 `. ]) r0 p% w
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ! x" A, ?+ j  L: f* e
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) v/ u% u& N6 T) H( a
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ) }. N% E" A4 N4 V
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : Q; o6 b! A8 |! P6 m' Q6 s1 l
7Kinki University School of Medicine, Osaka 589-8511, Japan
8 e) L  f6 v" d8Izumi Municipal Hospital, Osaka 594-0071, Japan
$ B% C1 X" ~3 K( K6 Y. x9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
/ D9 O- L% _" O/ f9 F. qCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp % [8 D3 e, [) X8 }* K/ m
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 1 d. ]4 S. f4 j0 m+ I; U& B

# K- @- h3 d3 B2 t  B# H
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type ' O; v0 o1 ]' @7 E

$ m+ T" O9 W& c1 I# sAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato % l% b: N4 C7 T* j) F4 X

% S, q9 _' S; N- CAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  / G9 M4 D, `3 ]9 E9 v
1 D5 R/ P5 [5 T. G1 N1 V
Published online on: Thursday, December 1, 2011   b5 [7 f# X. s; \. O. l
1 v) J: C9 A# K
Doi: 10.3892/ol.2011.507
  V# Z: D) ^6 p, O
/ E% y7 [2 B" EPages: 405-410 3 Y* |/ ?& O# {0 w; H! c
- Y2 Z2 m* r8 D5 A
Abstract:
6 s4 d9 R5 C* t4 b) yS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
) h5 s, {. D2 J0 Z( a2 N: h 5 y/ k2 C0 \, J% Q' v
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
# h8 ~% t- u, W3 a$ L8 ~0 TF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
4 I, {# F- m* B' X2 k8 a6 B4 M+ Author Affiliations
9 J, ?5 K# N: W7 s4 h+ U. [+ m1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 0 _# o. }( o+ v* j. z: l
2Department of Thoracic Surgery, Kyoto University, Kyoto % K4 w. c6 T8 e$ w
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan # f8 n3 B$ Y' f! j
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp , v% I6 k# l) {' o
Received September 3, 2010. ) A) b7 p1 q5 t$ z, L9 M' k, Y
Revision received November 11, 2010. : T7 X% Q0 J7 C; R# B
Accepted November 17, 2010.
9 x% M1 n: H. l. ]" UAbstract
( l! \2 H/ J) U# h* Y; A0 DBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
* V& h& C! O. Z- l1 q! ]# O3 IPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. % w  t+ T, p$ {7 }3 P7 f
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. + T! q/ [- D: N# f- B
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. ' S. Q3 B* y6 X$ a8 `
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。2 w' s' S+ H; J2 c
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?3 C4 S+ F7 X& l3 f8 w
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
, F' k% @3 D/ {' W- O  C2 S+ \' u5 M' hhttp://clinicaltrials.gov/ct2/show/NCT01523587
5 H) e' b0 h0 N; F. j8 L4 \8 t( O: _5 f* [$ A
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC& y' g: H0 ~# T; C$ J8 y
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
" L/ w, h- r% T4 ^+ J* s0 E5 v
0 e% {$ D+ |# ]8 @: o1 w; `从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。6 H2 e. h; @( x# t4 ?  W
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 8 t+ B; g$ K5 _+ t7 R: U8 _3 x
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
0 A! a( g' v1 e# |5 @% q4 Q至今为止,未出 ...
; p% I- s0 y9 t& p5 R  P
没有副作用是第一追求,效果显著是第二追求。3 s7 E& H1 ]* p% N
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表